Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary.
Current therapeutic strategies against glioblastoma (GBM) have failed to prevent disease progression and recurrence effectively. The part played by molecular imaging (MI) in the development of novel therapies has gained increasing traction in recent years. For the first time, using expertise from an integrated multidisciplinary group of authors, herein we present a comprehensive evaluation of state-of-the-art GBM imaging and explore how advances facilitate the emergence of new treatment options. We propose a novel next-generation treatment paradigm based on the targeting of multiple hallmarks of cancer evolution that will heavily rely on MI.
Funding is acknowledged within the context of the Irish National Biophotonics and Imaging Platform and the European Commission Framework Programme 7 AngioTox and AngioPredict initiatives
CommentsThis article is also available at http://europepmc.org/abstract/MED/23792334
Published CitationJarzabek MA , Sweeney KJ , Evans RL , Jacobs AH , Stupp R , O'Brien D , Berger MS , Prehn JH , Byrne AT. Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary. Drug Discovery Today. 2013;18(21-22):1052-1066.
- Beaumont Hospital
- Centre for Systems Medicine
- Physiology and Medical Physics